Study identification

EU PAS number

EUPAS1000000567

Study ID

1000000567

Official title and acronym

Real-world effectiveness of dabrafenib and trametinib in patients with BRAF-positive melanoma treated in routine Bulgarian clinical practice

DARWIN EU® study

No

Study countries

Bulgaria

Study description

Real-World Data Analysis of BRAF-Targeted Melanoma Therapy Compared to Clinical Trials Using Danny Platform

Study status

Finalised
Research institutions and networks

Institutions

Sqilline Health
Bulgaria
First published:
01/02/2024
Institution Non-Pharmaceutical company
The Bulgarian National Council on Prices and Reimbursement of Medicinal Products (NCPRMP)

Contact details

Alexandra Savova

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
No external funding
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable